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The value of an inflammation-based prognostic score (Glasgow Prognostic score, GPS) was compared with performance status
(ECOG-ps) in a longitudinal study of patients (n¼101) with inoperable non-small-cell lung cancer (NSCLC). At diagnosis, stratified
for treatment, only the GPS (HR 2.32, 95% CI 1.52–3.54, Po0.001) was a significant predictor of survival. In contrast, neither the
GPS nor ECOG-ps measured at 3–6 months follow-up were significant predictors of residual survival. This study confirms the
prognostic value of the GPS, at diagnosis, in patients with inoperable NSCLC. However, the role of the GPS and ECOG-ps during
follow-up has not been established.
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Non-small-cell lung cancer (NSCLC) is the most common cause of
cancer-related death in North America and Western Europe. Most
patients present with advanced inoperable disease and the majority
die within 12 months. Disease progression is associated with a
decline in both nutritional and functional status.
There is increasing evidence that the progressive decline of
patients with advanced cancer is, at least in part, secondary to the
presence of a systemic inflammatory response (Kotler, 2000; Scott
et al, 2002). For example, it has been shown that the presence of a
systemic inflammatory response, as evidenced by an elevated
circulating concentration of C-reactive protein and reduced
concentrations of albumin, is associated with poor survival
independent of stage and performance status in a variety of
common solid tumours (O’Gorman et al, 2000; Scott et al, 2002).
Specifically, we have shown that a combination of C-reac-
tive protein and albumin, the Glasgow Prognostic score (GPS),
has prognostic value, independent of performance status, in
patients with inoperable NSCLC (Forrest et al, 2003; Forrest et al,
2004).
In the above studies, the GPS was measured at diagnosis. To
date the value of the GPS as a method of monitoring of patients
with inoperable NSCLC has not been assessed. The aim of the
present study was, therefore, to examine, in a longitudinal study,
the prognostic value of GPS and performance status in patients
with inoperable NSCLC.
PATIENTS AND METHODS
Study design
Patients presenting with inoperable NSCLC (stages III and IV) to a
multidisciplinary clinic at Wishaw General Hospital, Lanarkshire
between January 2002 and December 2003 were studied prospec-
tively. All patients had cytologically or histologically confirmed
disease and were staged on the basis of clinical findings, chest X-
ray and, where appropriate, bronchoscopy, liver ultrasound,
isotope bone scan and computerised tomography of the thorax,
according to the American Thoracic Society TNM classification
(Mountain, 1991).
Weight, clinical stage and performance status (Eastern Co-
operative Oncology Group, ECOG-ps) were recorded at the time of
diagnosis. Performance status was assessed by a respiratory
physician (KD, HRS). A blood sample was also obtained, at
diagnosis, for measurement of white cell count, haemoglobin,
albumin and C-reactive protein concentrations. These measure-
ments were repeated 3–6 months after diagnosis.
Following diagnosis, patients were considered to have under-
gone active treatment if they received chemotherapy (mainly
cisplatin based) and/or radical radiotherapy. Patients receiving
palliative radiotherapy and/or palliative care (symptom control)
were considered to have had supportive treatment.
The study was approved by the Research Ethics Committee at
Wishaw General Hospital, Lanarkshire.
Methods
Blood parameters, routine laboratory measurements of haemoglo-
bin, white cell count, albumin and C-reactive protein concentra-
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stions were carried out. The coefficient of variation for these
methods, over the range of measurement, was less than 10% as
established by routine quality control procedures.
The GPS was constructed as previously described (Forrest et al,
2003). Briefly, patients with both an elevated C-reactive protein
(410mgl
 1) and hypoalbuminaemia (o35gl
 1) were allocated a
score of 2. Patients in whom only one of these biochemical
abnormalities was present were allocated a score of 1. Patients in
whom neither of these abnormalities was present were allocated a
score of 0.
Statistics
Univariate survival analysis was performed using the Kaplan–Meier
method with the log-rank test. Multivariate survival analysis and
calculation of hazard ratios (HR) were performed using the Cox
regression analysis. Deaths up to 30 November 2004 were included
in the analysis. Where appropriate, comparisons of data from
different time periods were carried out using the sign test. Analysis
was performed using SPSS software (SPSS Inc., Chicago, IL, USA).
RESULTS
The clinical characteristics of patients with inoperable NSCLC at
diagnosis are shown in Table 1. The majority were male, over the
age of 60 years and had ECOG-ps 0–1. Approximately half of the
patients had stage IV disease. A total of 68% patients had an
elevated C-reactive protein concentration; 10 patients had a low
albumin concentration. The majority of patients (69%) had an
abnormal GPS. In all, 42% of patients received active treatment.
During follow-up, 29 of 42 patients receiving active treatment
died. Of 59 patients, 55 receiving palliative treatment died. At
diagnosis, stratified for treatment, only the GPS (HR 2.32, 95% CI
1.52–3.54, Po0.001) was significantly associated with survival.
At the 3–6 months, 17 of the 42 patients who received active
treatment died and further seven patients were unfit to attend the
clinic, leaving 18 (43%) patients available for assessment. Of the 59
patients who received palliative treatment, 37 died and a further
two patients were unfit to attend the clinic, leaving 20 (34%)
patients available for the 3–6 month assessment (Table 2).
At the follow-up assessment (3–6 months), there was a
reduction in ECOG-ps (Po0.01) and the GPS (Po0.10). At this
time, stratified for treatment, neither ECOG-ps (P¼0.082) nor GPS
(P¼0.139) were significantly associated with subsequent survival.
DISCUSSION
The present study examined the longitudinal changes in an
inflammation-based prognostic score (GPS) and performance
status (ECOG-ps) in patients with inoperable NSCLC. Of the
initial 101 patients studied, only 38 were available for the follow-up
assessment. This high attrition rate is consistent with previous
Table 1 Diagnosis characteristics and survival of patients with inoperable
NSCLC
Patients Survival (months)
101 Median (95% CI) P-value
Age (years)
o60 18 11.9 (0.6–23.2)
X60 83 7.9 (6.3–9.6) 0.458
Sex
Male 62 8.6 (5.4–11.8)
Female 39 7.4 (5.0–9.8) 0.344
Stage
III 49 10.0 (7.2–12.8)
IV 52 6.2 (4.6–7.7) 0.067
Haemoglobin (g/l)
X12 67 8.4 (6.3–10.4)
o12 33 8.2 (2.5–14.0) 0.724
White cell count
p11 10
9/l 76 8.4 (6.4–10.4)
411 10
9/l 24 4.5 (0.0–10.4) 0.226
C-reactive protein (mg/l)
p10 33 11.6 (3.3–20.0)
410 68 7.3 (5.2–9.3) 0.006
Albumin (g/l)
X35 91 8.7 (6.9–10.5)
o35 10 1.2 (0.0–2.8) o0.001
ECOG-ps
0 17 14.8 (9.5–20.2)
1 44 6.5 (4.0–9.0)
2 30 8.4 (6.5–10.3)
3 10 1.2 (0.1–2.3) 0.003
GPS
0 32 11.6 (4.2–19.0)
1 59 8.4 (7.0–9.8)
2 10 1.2 (0–2.8) o0.001
Treatment
Active 42 15.5 (10.7–20.4)
Palliative 59 5.8 (3.7–7.9) o0.001
GPS¼Glasgow Prognostic score; 95% CI¼95% confidence interval; ECOG-
ps¼Eastern Co-operative Oncology Group.
Table 2 Parameters of patients with inoperable NSCLC at diagnosis and
3–6 months later
At diagnosis 3–6 months later
(n¼38) (n¼38) P-value
Age (years)
o60 8 (21)
X60 30 (79)
Sex
Male 27 (71)
Female 11 (29)
Stage
III 26 (68)
IV 12 (32)
Haemoglobin (g/l)
X12 21 (55) 20 (16)
o12 17 (45) 16 (42) 0.739
White cell count
p11 10
9/l 29 (76) 26 (68)
411 10
9/l 9 (24) 10 (26) 0.705
ECOG-ps
0 10 (26) 7 (18)
1 14 (37) 10 (26)
2 11 (29) 13 (34)
3 3 ( 8) 8 (21) 0.005
GPS
0 14 (37) 11 (29)
1 22 (58) 15 (40)
2 2 (5) 9 (24) 0.059
GPS¼Glasgow Prognostic score; ECOG-ps¼Eastern Co-operative Oncology
Group.
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slongitudinal studies of advanced cancer patients (McMillan et al,
1999; Vigano et al, 2000; Lundholm et al, 2004).
In the present study, at diagnosis, the GPS was superior to
ECOG-ps in predicting survival. Therefore, these results are
consistent with our previous cross-sectional studies of ECOG-ps
and the GPS (Forrest et al, 2003; Forrest et al, 2004).
In contrast, at the 3–6 month assessment, neither ECOG-ps nor
the GPS predicted survival independent of treatment. This
probably reflects the small numbers of patients studied at this
time. Also, the loss of prognostic value of ECOG-ps and the GPS at
this time may be related to the time-dependent nature of these
variables. For example, Vigano et al (2000) reported that, in
terminally-ill patients with advanced cancer, the predictive value of
both ECOG-ps and albumin concentrations decreased over time.
Prediction of survival in patients with common solid tumours
remains problematical despite the sophisticated mathematical
analyses and the many variables that have been analysed (Buccheri
and Ferrigno, 2004). Currently, stage and performance status are
the most commonly used routinely to assess likely outcome. The
present and previous studies of the GPS highlights the independent
value of the systemic inflammatory response as a prognostic factor
in inoperable NSCLC. This may be in part because the assessment
of stage and performance status reflects patient status at a specific
point in time. In contrast, the GPS, based as it is on
hypoalbuminaemia and the presence of an ongoing systemic
inflammatory response, not only reflects current nutritional status
but also predicts continuing nutritional decline of the patient
(McMillan et al, 1998; O’Gorman et al, 1999; McMillan et al, 2001).
The GPS may also have a prognostic role in patients with other
inoperable cancers. If this were to be the case, it would confirm the
general importance of the systemic inflammatory response and
suggest that the GPS may be useful as a framework to identify
other inflammation-derived symptoms in advanced cancer
patients. Finally, the GPS may be combined with other established
prognostic factors to improve the prediction of survival in the
patient with advanced cancer.
In summary, at diagnosis, the GPS is superior to ECOG-ps in
predicting survival, independent of treatment received, in patients
with inoperable NSCLC. As such, it offers the potential to stratify
patients at diagnosis and who are being considered for active
treatment. However, the role of the GPS or ECOG-ps during
routine follow-up has not been established.
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